NEXVIAZYME: payments to doctors
Payments that named NEXVIAZYME as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $920K
- Providers
- 800
- Transactions
- 1,805
- Average per transaction
- $510
The per-transaction average — $510 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 800 providers the average total is $1,150, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $739,512 | 80.4% |
| Sanofi-aventis U.S. LLC | $163,767 | 17.8% |
| Sanofi US Services Inc. | $16,837 | 1.8% |